AEMD — Aethlon Medical Income Statement
0.000.00%
Last trade - 00:00- $6.12m
- $1.30m
- 16
- 23
- 36
- 13
Annual income statement for Aethlon Medical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | C2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.65 | 0.659 | 0.294 | 0.574 | 0 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 7.03 | 8.55 | 10.7 | 12.6 | 12.6 |
| Operating Profit | -6.38 | -7.89 | -10.4 | -12 | -12.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.38 | -7.89 | -10.4 | -12 | -12.2 |
| Net Income After Taxes | -6.38 | -7.89 | -10.4 | -12 | -12.2 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.37 | -7.89 | -10.4 | -12 | -12.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.37 | -7.89 | -10.4 | -12 | -12.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -17.4 | -6.52 | -7.06 | -5.79 | -4.86 |